细菌性阴道病药物市场规模预计将从 2024 年的 21.5 亿美元增至 2031 年的 38.2 亿美元。预计 2024-2031 年期间市场复合年增长率将达到 8.3%。在预测期内,人们对微生物组疗法和益生菌的偏好日益增加,可能会带来新的市场趋势。
细菌性阴道病药物市场分析
细菌性阴道病(BV)是育龄妇女常见的一种疾病,一般是由阴道正常菌群变化引起的。BV 的特征是乳酸杆菌种群减少,厌氧菌如解脲支原体、阴道加德纳菌、动弯杆菌种群、人型支原体和普氏菌种群增加。无保护的性交和频繁灌洗等活动进一步增加了 BV 的风险。该病的常见症状包括阴道分泌物异常、异味和瘙痒。根据 2023 年在 ScienceDirect Journal 上发表的《欧洲妇产科和生殖生物学杂志》文章,BV 的全球患病率为 23% 至 29%,在孕妇中,患病率为 11% 至 49%。根据 Medscape 在 2024 年的报告,美国每年约有三分之一的成年女性(约 2200 万)受到细菌性阴道炎的影响,每年有 1000 万女性因阴道分泌物问题到诊所就诊。细菌性阴道炎会带来早产、流产以及增加对 HIV 和其他性传播感染的易感性等风险。细菌性阴道炎发病率的不断上升,加上潜在的并发症,促使女性寻求医疗救治和药物干预,从而对有效药物产生了巨大的需求。细菌性阴道炎复发的可能性很高,因此需要开发治疗方案来预防复发。随着全球尤其是新兴市场的医疗保健可及性的改善,现在越来越多的女性正在寻求治疗细菌性阴道炎的方法,从而推动细菌性阴道病药物市场的增长
细菌性阴道病药物市场概况
由于细菌性阴道病发病率不断上升,以及人们对开发新型靶向疗法的关注度不断提高,细菌性阴道病药物市场正在迅速扩张。市场上的知名企业正致力于创新和合作,以提高产品可用性。然而,高复发率和治疗依从性挑战阻碍了细菌性阴道病药物市场的增长。
定制此报告以满足您的需求
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
- 获取此报告的关键市场趋势。这个免费样品将包括数据分析,从市场趋势到估计和预测。
细菌性阴道病药物市场驱动因素和机遇
更加注重开发新型靶向疗法推动市场增长
制药公司和研究机构不断致力于开发创新疗法,以针对 BV 的根本原因,同时提高现有药物的安全性和有效性。以前的 BV 治疗包括抗生素,如甲硝唑和克林霉素,它们通过消除阴道内有害细菌的过度生长起作用。然而,高复发率和潜在的副作用,如胃肠道问题和酵母菌感染,是这些治疗的典型局限性。这一缺点促使人们开发出更先进、更有针对性的疗法,以最小的副作用提供更好的患者治疗效果。BV 治疗的显著改进包括开发单剂量疗法,如塞克硝唑,这是一种口服抗生素,其疗效与标准疗法相似,但给药时间更方便,副作用更少。塞克硝唑因其高治愈率和与较长的多剂量抗生素方案相比降低 BV 复发风险的能力而广受欢迎。这种向更有利于患者的治疗方案转变促进了细菌性阴道病药物市场的增长,因为患者更有可能遵循简单的治疗方案。因此,新型药物(如塞克硝唑)和创新药物输送系统(包括阴道凝胶和插入物)的增加有助于提高治疗依从性并最大限度地减少副作用,从而促进了细菌性阴道病药物市场的增长。
市场参与者的战略举措,创造有利可图的市场机会
在细菌性阴道病药物市场运营的公司不断关注战略发展,例如产品审批、合作、融资、协议和新产品发布,这有助于他们提高销售额、扩大地理覆盖范围并增强满足现有客户群需求的能力。以下是细菌性阴道病药物市场主要参与者的一些战略举措。
- 2024 年 11 月,Freya Biosciences 获得了比尔和梅琳达·盖茨基金会 1040 万美元的战略投资,以及来自现有投资者丹麦出口和投资基金 (EIFO) 的 140 万美元额外融资。该公司计划利用这些资金开发用于治疗 BV 的微生物免疫疗法,以解决早产风险以及其他可能影响产妇和新生儿健康的适应症。
- 2022 年 3 月,Organon 与 Daré Bioscience, Inc. 达成协议,Organon 将授予 XACIATO(克林霉素磷酸盐阴道凝胶,2%)的全球权利。凭借此协议,XACIATO 获得了美国食品药品管理局 (FDA) 颁发的合格传染病产品 (QIDP) 和快速通道资格,可用于治疗细菌性阴道病。
- 2022年2月,鲁宾制药公司(Lupin Pharmaceuticals Inc.)获得FDA批准,提交补充新药申请(sNDA),以增加 SOLOSEC(塞克硝唑)在12岁或以上女性患者中治疗细菌性阴道病的使用;该批准还包括治疗该年龄段患者的滴虫病。
- 2021年12月,FDA 批准了Daré Bioscience, Inc.生产的XACIATO(克林霉素磷酸盐阴道凝胶,2%)用于治疗12岁以上女性的细菌性阴道病。
- 2021 年 2 月,Rebiotix (Ferring) 和 MyBiotics 合作开发基于活微生物组的疗法,用于生殖医学和孕产妇健康。此次合作旨在为育龄妇女的细菌性阴道病开发基于活微生物组的生物疗法,这种疾病可能与流产风险增加以及妊娠和生育并发症有关。
因此,持续的资金、产品发布和批准以及合作预计将为未来几年细菌性阴道病药物市场的增长创造充足的机会。
细菌性阴道病药物市场报告细分分析
有助于得出细菌性阴道病药物市场分析的关键部分是类型、给药途径、剂型和分销渠道。
- 根据类型,细菌性阴道病药物市场分为处方药和非处方药。处方药在 2024 年占据了更大的市场份额。
- 就给药途径而言,细菌性阴道病药物市场分为口服、阴道和外用。口服药物在 2024 年占据市场主导地位。
- 就剂型而言,细菌性阴道病药物市场分为药丸、乳膏、凝胶、溶液/洗剂等。2024 年,药丸占据了市场主导地位。
- 就分销渠道而言,细菌性阴道病药物市场分为医院药房、网上药房和零售药房。2024 年,医院药房占据了市场主导地位。
细菌性阴道病药物市场份额按地区分析
细菌性阴道病药物市场报告的地理范围主要集中在五个地区:北美、亚太地区、欧洲、南美和中美以及中东和非洲。在收入方面,北美在 2024 年占据了市场主导地位。预计在预测期内它将主导全球市场。美国是世界上最大的细菌性阴道病药物市场。在美国,由于 BV 患病率的增加、人们对女性健康的认识的提高以及不断努力开发创新治疗方法,细菌性阴道病药物市场正在经历显着增长。BV 是女性最常见的阴道感染之一,尤其影响育龄女性。根据 Medscape 在 2024 年的一份报告,美国约三分之一的成年女性,即约 2200 万女性,每年受到 BV 的影响,1000 万女性因阴道分泌物异常而就诊。它通常与性活动、冲洗和荷尔蒙变化等因素有关;尽管如此,细菌性阴道炎的确切病因仍不确定。治疗细菌性阴道炎的主要治疗选择包括美国食品药品监督管理局 (FDA) 批准的抗生素,如甲硝唑和克林霉素。甲硝唑通常以口服和外用形式提供,被认为是细菌性阴道炎的一线治疗药物。克林霉素也常以口服和外用形式提供。益生菌和噬菌体疗法等较新的药物和配方也正在出现,以帮助恢复天然阴道菌群,从而减少细菌性阴道炎的复发。
美国政府的举措在提高和传播人们对阴道病的认识方面发挥着关键作用。美国国立卫生研究院 (NIH) 资助对细菌性阴道病的病因、治疗和预防的研究。NIH 的努力使人们对微生物群及其在细菌性阴道病的致病中的作用有了更深入的了解,这对于开发更有针对性的治疗方法至关重要。美国疾病控制和预防中心 (CDC) 提供了指导方针和建议,以改善细菌性阴道病的诊断和管理。这些举措有助于标准化护理并确保患者得到最有效的治疗。此外,美国国家儿童健康和人类发展研究所 (NICHD,一个联邦机构) 和 NIH 致力于了解细菌性阴道病并教育女性了解其病因和预防方法。NICHD 资助并开展与细菌性阴道病相关的风险及其预防和治疗方法的研究。
细菌性阴道病药物市场区域洞察
Insight Partners 的分析师已详细解释了预测期内影响细菌性阴道病药物市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的细菌性阴道病药物市场细分和地理位置。

- 获取细菌性阴道病药物市场的区域特定数据
细菌性阴道病药物市场报告范围
报告属性 | 细节 |
---|---|
2024 年的市场规模 | 21.5亿美元 |
2031 年市场规模 | 38.2亿美元 |
全球复合年增长率(2024 - 2031) | 8.3% |
史料 | 2021-2023 |
预测期 | 2024-2031 |
涵盖的领域 | 按类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
细菌性阴道病药物市场参与者密度:了解其对业务动态的影响
细菌性阴道病药物市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求又源于消费者偏好的不断变化、技术进步以及对产品益处的认识不断提高等因素。随着需求的增加,企业正在扩大其产品范围,进行创新以满足消费者的需求,并利用新兴趋势,从而进一步推动市场增长。
市场参与者密度是指在特定市场或行业内运营的企业或公司的分布情况。它表明在给定市场空间中,相对于其规模或总市场价值,有多少竞争对手(市场参与者)存在。
在细菌性阴道病药物市场运营的主要公司有:
- 拜耳公司
- 辉瑞公司
- 赛诺菲公司
- 星药控股有限公司
- Viatris 公司
- 格兰马克制药有限公司
免责声明:上面列出的公司没有按照任何特定顺序排列。

- 了解细菌性阴道病药物市场顶级关键参与者概况
细菌性阴道病药物市场新闻和最新进展
细菌性阴道病药物市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。细菌性阴道病药物市场见证的一些关键发展如下:
- VivaGel BV 销售 Starpharma 签署合作伙伴关系,在 MENA 地区分销 VivaGel BV 产品,并签署分销协议 – MENA 地区。(来源:Starpharma Holdings Limited,新闻稿,2024 年 1 月)
- Organon 的 XACIATO(磷酸克林霉素)阴道凝胶 2% 在全国范围内上市,用于治疗 12 岁及以上女性的细菌性阴道炎。(来源:Lupin,新闻稿,2024 年 1 月)
- Glenmark Pharmaceuticals 获得了 0.75% 甲硝唑阴道凝胶的 ANDA 批准。(来源:Glenmark Pharmaceuticals Inc.,新闻稿,2022 年 1 月)
- Lupin 宣布 FDA 批准 SOLOSEC(塞克硝唑)的 sNDA,以扩大其在青少年中的使用范围,用于治疗女性细菌性阴道病和滴虫病。(来源:Lupin,新闻稿,2022 年 2 月)
细菌性阴道病药物市场报告覆盖范围和交付成果
“细菌性阴道病药物市场规模和预测(2021-2031 年)”报告对以下领域进行了详细的市场分析:
- 细菌性阴道病药物市场规模及全球、区域和国家层面所有主要细分市场的预测
- 细菌性阴道病药物市场趋势,以及驱动因素、限制因素和关键机遇等市场动态
- 详细的 PEST 和 SWOT 分析
- 细菌性阴道病药物市场分析涵盖主要市场趋势、全球和区域框架、主要参与者、法规和最新市场发展
- 行业格局和竞争分析,涵盖市场集中度、热图分析、知名参与者以及细菌性阴道病药物市场的最新发展
- 详细的公司简介
- 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
- PEST 和 SWOT 分析
- 市场规模价值/数量 - 全球、区域、国家
- 行业和竞争格局
- Excel 数据集



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
常见问题
The market is expected to register a CAGR of 8.3% during 2024–2031.
The bacterial vaginosis drug market value is expected to reach US$ 3.82 billion by 2031.
Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key players operating in the market.
Inclination toward microbiome therapies and probiotics are likely to emerge as new growth trends in the market in the coming years.
Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are among the most significant factors fueling the market growth.
North America dominated the market in 2023.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Bacterial Vaginosis Drug Market
- Bayer AG
- Pfizer Inc
- Sanofi SA
- Starpharma Holdings Limited
- Viatris Inc.
- Glenmark Pharmaceuticals Ltd
- Lupin Ltd
- Sun Pharmaceutical Industries Ltd
- Organon & Co
- Duchesnay Inc., Canada
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.